Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
RBX2660 as stool-derived enema formulation is developed by Rebiotix Inc.
Fecal microbiota RBX2660 is the first single-dose, microbiota-based live biotherapeutic product (LBP) approved by the US Food and Drug Administration (FDA) for the prevention of recurrence of CDI in adults, following antibiotic treatment for Clostridioides difficile infection (CDI) (recurrent)
RBX2660 is a product derived from human fecal matter, which is o…